ArticleBlood2018
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of thalidomide in β-thalassaemia: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Contemporary Management of Thalassemia: A Perspective on Current Standards and the Emergence of FDA-Approved Oral Therapy.Health science reports · 2026Article
- Thalassaemia.Nature reviews. Disease primers · 2026Review
- Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting.Frontiers in immunology · 2026Review
- Extramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival.Hematology, transfusion and cell therapy · 2024Article
- Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach.International journal of hematology · 2024Review
- Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis.Haematologica · 2023Review
- Article
- Non-Transfusion-Dependent Thalassemia: A Panoramic Review.Medicina (Kaunas, Lithuania) · 2022Review
- The Roles of Mitophagy and Autophagy in Ineffective Erythropoiesis in β-Thalassemia.International journal of molecular sciences · 2022Review
- The unexpected impact of cabozantinib on red blood cells consumption in patients with transfusion-dependent thalassemia.Annals of hematology · 2022Article
- Advancing the care of β-thalassaemia patients with novel therapies.Blood transfusion = Trasfusione del sangue · 2022Review
- β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.Hematology. American Society of Hematology. Education Program · 2021Review
- JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics.Annals of hematology · 2021Article
- Review
- The Role of Iron in Benign and Malignant Hematopoiesis.Antioxidants & redox signaling · 2021Review
- Innovative Treatments for Rare Anemias.HemaSphere · 2021Review
- Review
- Review
- Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.Hematology. American Society of Hematology. Education Program · 2018Review
Corrections and comments
- Comment on
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.